New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera

BURLINGTON, Mass., August 04, 2023--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the publication of a cost-effectiveness analysis of ropeginterferon alfa-2b-njft (marketed as BESREMi®) in the Journal of Comparative Effectiveness Research. The analysis, titled "Cost-Effectiven

Related Keywords

United States ,Japan ,South Korea ,Taiwan ,China ,Taipei ,T Ai Pei ,Taiwanese ,American ,Raymond Urbanski ,Pharmaessentia Tpex ,Aaron Gerds ,Ann Hematol ,Pharmaessentia United States Corporation ,Institute For Clinical ,Pharmaessentia Corporation ,Journal Of Comparative Effectiveness Research ,Pharmaessentia Corporation Tpex ,Linkedin ,Affairs At Pharmaessentia ,Us Head Of Clinical Development ,Case Comprehensive Cancer Center ,National Comprehensive Cancer Network ,Bonafedem Health Care ,European Medicines Agency ,Comparative Effectiveness Research ,Comparative Effectiveness ,Polycythemia Vera ,Medical Director ,Senior Vice President ,Clinical Development ,Medical Affairs ,Pharmaessentia United States ,Peripheral Blood Counts ,Reproductive Potential ,Prescribing Information ,Private Securities Litigation Reform Act ,What We Know ,What We Do Not Know ,Emerging Treatment ,Clin Oncol ,Care Costs ,Thromboembolic Events ,Hydroxyurea Treated Patients ,Economic Review ,Fibrotic Progression ,Essential Thrombocythemia ,Literature Review ,Cost Effectiveness Analysis ,Tv ,Healthcare System ,Effective Therapy ,Interferon Alfa 2b ,